EPO Reversal Overturns Copaxone 40mg Patent
Mylan Celebrates Invalidation Of European Dosing-Regimen Intellectual Property
Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.
